vs
Side-by-side financial comparison of MFA FINANCIAL, INC. (MFA) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $55.5M, roughly 1.0× MFA FINANCIAL, INC.). On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 9.2%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 7.7%).
MFA Financial, Inc. is a U.S.-headquartered real estate investment trust (REIT) specializing in investing in and managing residential and commercial mortgage-backed securities, mortgage loans, and other real estate-related financial assets. It caters primarily to institutional and individual investors across the U.S., focusing on delivering stable risk-adjusted returns via rigorous asset screening and risk management frameworks.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
MFA vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $55.5M | $57.3M |
| Net Profit | — | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 97.9% | -82.2% |
| Net Margin | — | -83.0% |
| Revenue YoY | 9.2% | 36.9% |
| Net Profit YoY | — | -9.6% |
| EPS (diluted) | $0.43 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $55.5M | $57.3M | ||
| Q3 25 | $56.8M | $51.3M | ||
| Q2 25 | $61.3M | $48.5M | ||
| Q1 25 | $57.5M | $32.7M | ||
| Q4 24 | $50.8M | $41.8M | ||
| Q3 24 | $50.6M | $33.3M | ||
| Q2 24 | $53.5M | $29.1M | ||
| Q1 24 | $47.8M | $26.0M |
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $48.1M | $-52.9M | ||
| Q2 25 | $33.2M | $-46.6M | ||
| Q1 25 | $41.2M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $48.2M | $-43.6M | ||
| Q2 24 | $41.9M | $-32.3M | ||
| Q1 24 | $23.2M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 97.9% | -82.2% | ||
| Q3 25 | 84.5% | -102.6% | ||
| Q2 25 | 54.5% | -93.4% | ||
| Q1 25 | 70.0% | -143.7% | ||
| Q4 24 | 6.8% | -98.6% | ||
| Q3 24 | 98.2% | -132.0% | ||
| Q2 24 | 79.1% | -139.2% | ||
| Q1 24 | 50.7% | -538.7% |
| Q4 25 | — | -83.0% | ||
| Q3 25 | 84.7% | -103.1% | ||
| Q2 25 | 54.2% | -96.1% | ||
| Q1 25 | 71.6% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | 95.2% | -131.2% | ||
| Q2 24 | 78.4% | -110.9% | ||
| Q1 24 | 48.5% | -544.4% |
| Q4 25 | $0.43 | $-0.73 | ||
| Q3 25 | $0.35 | $-0.82 | ||
| Q2 25 | $0.21 | $-0.75 | ||
| Q1 25 | $0.31 | $-0.81 | ||
| Q4 24 | $-0.01 | $-0.71 | ||
| Q3 24 | $0.37 | $-0.73 | ||
| Q2 24 | $0.32 | $-0.55 | ||
| Q1 24 | $0.14 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $213.2M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.8B | $139.1M |
| Total Assets | $13.0B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $213.2M | $388.9M | ||
| Q3 25 | $305.2M | $416.1M | ||
| Q2 25 | $275.7M | $291.0M | ||
| Q1 25 | $253.7M | $314.5M | ||
| Q4 24 | $338.9M | $320.6M | ||
| Q3 24 | $305.6M | $298.4M | ||
| Q2 24 | $289.4M | $319.1M | ||
| Q1 24 | $306.3M | $201.2M |
| Q4 25 | $1.8B | $139.1M | ||
| Q3 25 | $1.8B | $148.8M | ||
| Q2 25 | $1.8B | $-11.9M | ||
| Q1 25 | $1.8B | $18.9M | ||
| Q4 24 | $1.8B | $21.7M | ||
| Q3 24 | $1.9B | $11.2M | ||
| Q2 24 | $1.9B | $39.3M | ||
| Q1 24 | $1.9B | $61.6M |
| Q4 25 | $13.0B | $480.2M | ||
| Q3 25 | $12.1B | $506.9M | ||
| Q2 25 | $11.7B | $372.7M | ||
| Q1 25 | $11.5B | $386.7M | ||
| Q4 24 | $11.4B | $392.3M | ||
| Q3 24 | $11.2B | $363.6M | ||
| Q2 24 | $11.1B | $381.8M | ||
| Q1 24 | $10.9B | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $76.2M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $76.2M | $-25.4M | ||
| Q3 25 | $14.7M | $-26.6M | ||
| Q2 25 | $38.5M | $-23.3M | ||
| Q1 25 | $-14.6M | $-40.4M | ||
| Q4 24 | $200.1M | $-18.8M | ||
| Q3 24 | $-11.3M | $-25.2M | ||
| Q2 24 | $46.5M | $-29.1M | ||
| Q1 24 | $53.5M | $-40.7M |
| Q4 25 | — | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | -0.35× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.23× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 2.30× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
